Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 2, 2026

Cultivating Ex Vivo Patient-Derived Glioma Organoids Using a Tissue Chopper
05:45

Cultivating Ex Vivo Patient-Derived Glioma Organoids Using a Tissue Chopper

Published on: January 19, 2024

High-grade gliomas.

Brett J Theeler1, Morris D Groves

  • 1Department of Neuro-Oncology, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 0431, Houston, TX, 77030-4009, USA.

Current Treatment Options in Neurology
|April 19, 2011
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trial.

Neuro-oncology advances·2026
Same author

The relationship between asthma and glioma: a case-control study in a universal access healthcare system.

Journal of neuro-oncology·2026
Same author

Unexplained cerebral hemiatrophy in a case of astrocytoma, IDH-Mutant, WHO grade 3: a case report and literature review.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2025
Same author

Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.

Nature medicine·2025
Same author

The COVID-19 pandemic experience for patients with central nervous system tumors: Differences in patient-reported outcomes and practice recommendations.

Neuro-oncology practice·2025
Same author

Comparative Analysis of Treatment Patterns in DoD Beneficiaries With Malignant Central Nervous System Tumors: A Focus on Care Setting.

Military medicine·2024
Same journal

Visual Impairment and Driving in Older Adults: A Narrative Review.

Current treatment options in neurology·2026
Same journal

Non-Cognitive Symptoms in Alzheimer's Disease and Their Likely Impact on Patient Outcomes. A Scoping Review.

Current treatment options in neurology·2026
Same journal

Update on the Treatment of Autonomic Disorders.

Current treatment options in neurology·2025
Same journal

Primary Progressive Aphasia Treatment: Current Treatment Options in Neurology Article Topic: Management of Primary Progressive Aphasia.

Current treatment options in neurology·2025
Same journal

Emerging Principles for Treating Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD).

Current treatment options in neurology·2025
Same journal

Diagnosis and Management of Progressive Corticobasal Syndrome.

Current treatment options in neurology·2025
See all related articles

High-grade gliomas require maximal surgical resection and radiotherapy. Standard treatment for glioblastoma involves concurrent and adjuvant temozolomide (TMZ), while chemotherapy roles in anaplastic gliomas are still evolving.

Area of Science:

  • Neuro-oncology
  • Radiation Oncology
  • Medical Oncology

Background:

  • High-grade gliomas (HGGs) necessitate aggressive treatment strategies.
  • Current standards involve surgery, radiotherapy, and chemotherapy, with evolving roles for specific agents.
  • Optimal management for recurrent or anaplastic gliomas remains an area of active investigation.

Purpose of the Study:

  • To outline current treatment paradigms for high-grade gliomas.
  • To discuss the role of radiotherapy and chemotherapy, including temozolomide (TMZ) and procarbazine, lomustine, vincristine (PCV).
  • To highlight the importance of clinical trials and molecularly targeted therapies for HGGs.

Main Methods:

  • Review of established treatment protocols for newly diagnosed and recurrent HGGs.

More Related Videos

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

Related Experiment Videos

Last Updated: Jun 2, 2026

Cultivating Ex Vivo Patient-Derived Glioma Organoids Using a Tissue Chopper
05:45

Cultivating Ex Vivo Patient-Derived Glioma Organoids Using a Tissue Chopper

Published on: January 19, 2024

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

  • Discussion of standard-of-care regimens including surgery, radiotherapy (57-60 Gy), and chemotherapy (TMZ, PCV).
  • Consideration of emerging therapies and the importance of molecular profiling.

    • Main Results:

    • Maximal safe surgical resection followed by radiotherapy is the cornerstone for HGGs.
    • Concurrent and adjuvant temozolomide (TMZ) is standard for newly diagnosed glioblastoma.
    • Chemotherapy's role in anaplastic gliomas and recurrent glioblastoma requires further clarification, with bevacizumab and dose-intense TMZ as options.

    Conclusions:

    • Treatment for HGGs integrates surgery, radiotherapy, and chemotherapy, with TMZ being central for glioblastoma.
    • Further research is needed to define optimal chemotherapy strategies for anaplastic gliomas and recurrent disease.
    • Future directions emphasize molecularly targeted agents and clinical trial participation for all HGG patients.